Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 4, 2002, Pages 369-377

  Alban, Susanne ^a   Welzel, Dieter ^a   Hemker, H Coenraad ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Low molecular weight heparin; Medium molecular weight heparin; Pharmacodynamics; Pharmacokinetics; Unfractionated heparin

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; MEDIUM MOLECULAR WEIGHT HEPARIN; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; HUMAN; MALE; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ANTITHROMBIN III; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENOXAPARIN; FACTOR XA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PHARMACOKINETICS;

EID: 0036687416     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34306     Document Type: Article

References (40)

1. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
2. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
3. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin
4. Binding and endocytosis of heparin by human endothelial cells in culture
5. New antithrombotic agents
6. New anticoagulant drugs
7. Fondaparinux: A synthetic heparin pentasaccharide as a new antithrombotic agent
8. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95. Intestinal absorption properties, biochemical and pharmacodynamic effects
9. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma
10. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats
11. Conjectures and refutations on the mode of action ofheparins
12. The mode of action of heparin in plasma
13. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
14. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood
15. Synergism between full length TFPI and heparin: Evidence for TFPI as an important factor for the antithrombotic activity of heparin
16. Heparin/low molecular weight heparin and tissue factor pathway inhibitor
17. Heparin oligosaccharides: New analogues development and applications
18. Heparin and cancer
19. Oligosaccharide mapping of low molecular weight heparins: Structure and activity differences
20. Structure-activity relationship in heparin. A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
21. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans
22. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins
23. Minimalanforderungen zur gewinnung von citratplasma für hämostaseologische analysen
24. Statistical moments in pharmacokinetics
25. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits
26. Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction
27. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis
28. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis
29. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model
30. Biochemical and pharmacologic profile of defined molecular weight fractions of heparin
31. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs)
32. Characterization of the structural requirements for a carbohydrate based anticoagulant with reduced risk of inducing the immunological type of heparin-associated thrombocytopenia
33. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin
34. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fraction
35. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation